You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020158028
Dec 202040012
Jan 20213806
Feb 20212806
Mar 202160014
Apr 202142012
May 202116010
Jun 2021005
Jul 20210012
Aug 20210012
Sep 2021009
Oct 202124020
Nov 202117019
Dec 20211602
Jan 20222804
Feb 20222006
Mar 20223005
Apr 202248015
May 20226009
Jun 20223006
Jul 20224803
Aug 20222603
Sep 20221201
Oct 20221605
Nov 20222002
Dec 20223202
Jan 20233002
Feb 20233405
Mar 202324011
Apr 20232608
May 20231402
Jun 20231200
Jul 20231609
Aug 20232402
Sep 20231200
Oct 20231006
Nov 20231602
Dec 20232600
Jan 20242401
Feb 20242201
Mar 20242000
Apr 20243408
May 20242202
Jun 20242602
Jul 20242802
Aug 20242202
Sep 20244203
Total12930296